Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

When companies post strong earnings, the stock generally performs well, just like Pfizer Inc.'s ( NYSE:PFE ) stock ...

Below is some historical data on the post-earnings performance of Pfizer stock compared to the stock performance of peers that reported their earnings just before Pfizer. For a fair comparison ...

Still, Pfizer stock has fallen 10% year to date and hasn’t provided the defensive hedge that many of its Zacks Large Cap Pharmaceutical peers have been able to provide, such as AbbVie ABBV ...